Leerink Partners Issues Pessimistic Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price objective cut by Leerink Partners from $154.00 to $140.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Leerink Partners‘s price target suggests a potential upside of 49.38% from the stock’s previous close.

A number of other equities analysts have also recently weighed in on the company. Citigroup lifted their price target on Mirum Pharmaceuticals from $160.00 to $184.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. Robert W. Baird upped their price objective on shares of Mirum Pharmaceuticals from $123.00 to $130.00 and gave the company an “outperform” rating in a research note on Tuesday, September 29th. Weiss Ratings cut shares of Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, October 22nd. Royal Bank Of Canada reissued an “outperform” rating and issued a $155.00 target price on shares of Mirum Pharmaceuticals in a research report on Wednesday. Finally, Evercore restated an “outperform” rating and set a $146.00 price target on shares of Mirum Pharmaceuticals in a report on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Mirum Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $154.94.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM traded up $0.18 during trading on Thursday, hitting $93.72. The company had a trading volume of 722,713 shares, compared to its average volume of 710,635. The company has a market cap of $6.09 billion, a P/E ratio of -6.06 and a beta of 0.75. Mirum Pharmaceuticals has a 52 week low of $63.23 and a 52 week high of $130.00. The business’s 50-day moving average is $89.29 and its 200 day moving average is $98.46. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.38). The company had revenue of $185.72 million for the quarter, compared to the consensus estimate of $178.07 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%. The business’s revenue was up 39.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.05 earnings per share. Equities research analysts predict that Mirum Pharmaceuticals will post -1.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 6,001 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $99.90, for a total transaction of $599,499.90. Following the completion of the sale, the chief financial officer directly owned 36,355 shares in the company, valued at approximately $3,631,864.50. This trade represents a 14.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 658 shares of Mirum Pharmaceuticals stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $100.00, for a total value of $65,800.00. Following the transaction, the senior vice president directly owned 616 shares in the company, valued at approximately $61,600. This trade represents a 51.65% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 116,659 shares of company stock valued at $11,404,100. Corporate insiders own 8.32% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Jupiter Topco LLC purchased a new position in Mirum Pharmaceuticals during the second quarter valued at approximately $691,672,000. BlackRock Inc. purchased a new stake in Mirum Pharmaceuticals in the 2nd quarter worth approximately $513,945,000. William Blair Investment Management LLC purchased a new stake in Mirum Pharmaceuticals in the 2nd quarter worth approximately $164,453,000. Janus Henderson Group PLC boosted its stake in shares of Mirum Pharmaceuticals by 14.5% during the 1st quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock valued at $641,764,000 after buying an additional 880,505 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter valued at $78,434,000.

More Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $202 price target, while still projecting a path to higher earnings over the longer term; its FY2030 EPS estimate rose to $10.76 from $10.03. HC Wainwright estimates
• Positive Sentiment: Mirum’s latest quarter showed revenue up 39.6% year over year to $185.72 million, ahead of analyst expectations. The stock also moved above its 50-day moving average after the earnings release, a potentially supportive technical signal. Stock crosses 50-day moving average
• Neutral Sentiment: Leerink Partners lowered its price target to $140 from $154 but kept an “Outperform” rating. That reflects reduced upside expectations while retaining a positive view of the shares. Leerink Partners rating
• Negative Sentiment: HC Wainwright substantially cut EPS estimates for 2026 and 2027, shifting its FY2027 forecast from a $1.16 profit to a $1.28 loss. It also reduced its FY2028 estimate from $5.38 to $2.64 and FY2029 from $7.21 to $6.85, indicating weaker expected earnings in the coming years despite the maintained Buy rating. HC Wainwright revised EPS estimates
• Negative Sentiment: Quarterly EPS was a loss of $0.87, wider than the expected $0.49 loss. The earnings shortfall tempers the revenue beat and may weigh on investor sentiment. Earnings and stock outlook
• Negative Sentiment: CEO Christopher Peetz sold 20,000 shares worth $1.8 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan, which may soften its significance but can still draw investor attention. CEO share sale

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly disorders affecting the liver and bile acid pathways. The company’s medicines are designed to address conditions with limited treatment options and to improve outcomes for children and adults living with serious chronic diseases.

Mirum’s lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor used to treat cholestatic pruritus, or severe itching caused by impaired bile flow, in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.